Article Information
History
- December 17, 2017.
Article Versions
- Version 1 (September 17, 2017 - 07:58).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Arnoud Boot1,2,
- Mi Ni Huang1,2,
- Alvin W.T. Ng2,3,
- Szu-Chi Ho1,
- Jing Quan Lim4,5,
- Yoshiiku Kawakami6,
- Kazuaki Chayama6,
- Bin Tean Teh7,
- Hidewaki Nakagawa8 and
- Steven G. Rozen1,2,*
- 1Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, 169857, Singapore
- 2Centre for Computational Biology, Duke-NUS Medical School, 8 College Road, 169857, Singapore
- 3NUS Graduate School for Integrative Sciences and Engineering, 28 Medical Drive, 117456, Singapore
- 4Laboratory of Cancer Epigenome, Division of Medical Science, National Cancer Centre Singapore, 169610, Singapore
- 5Lymphoma Genomic Translational Research Laboratory, Division of Medical Oncology, National Cancer Centre Singapore, 169610, Singapore
- 6Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan
- 7Division of Medical Sciences, National Cancer Centre Singapore.
- 8Laboratory for Genome Sequencing Analysis, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan.
- ↵*Corresponding author: Steven G. Rozen, steve.rozen{at}duke-nus.edu.sg
Posted December 17, 2017.
In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors
